After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech firm developing targeted therapies for genetic medicine delivery, announced a definitive agreement for the immediate cash exercise of outstanding warrants totaling 6,595,000 shares of common stock at a reduced price of $0.70 per share. The transaction is expected to generate approximately $4.6 million in gross proceeds. In exchange, the company will issue new unregistered warrants with the same share count, exercisable in six months at $0.70 and valid for five and a half years. Ladenburg Thalmann & Co. Inc. is serving as exclusive placement agent. Calidi plans to use the net proceeds to support its clinical and pre-clinical programs, operations and working capital.
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.
Get a pulse on the US markets on Wednesday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.
NetworkNewsWire Editorial Coverage : Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to rise in the coming decades. By 2050, the American Cancer Society estimates that annual cancer diagnoses will reach 35 million. While advances in treatment have improved outcomes for some patients, the demand for more effective therapies remains urgent — and the opportunity for innovation and market impact is significant. Calidi Biotherapeutics Inc. (NYSE American: CLDI) ( Profile ) is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors. Using engineered viruses to transport therapeutic payloads with precision, Calidi’s technology aims to transform the landscape of cancer treatment. Though oncology is its initial focus, the company is also exploring broader applications in high-need areas such as autoimmune disorders. In doing so, Calidi is positioning itself among a select group of biotech innovators, including Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), ImmunityBio Inc. (NASDAQ: IBRX) , Crispr Therapeutics AG (NASDAQ: CRSP) and…
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Calidi Biotherapeutics (NYSE: CLDI) surged 39.47% after hours Tuesday, following renewed investor interest in its innovative cancer treatment developments.
Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company’s precision genetic medicine platform, which targets both primary and metastatic cancer tumors using engineered viruses. With global cancer diagnoses expected to reach 35 million annually by 2050, Calidi’s approach represents a potential breakthrough in addressing critical unmet needs. The company’s platform aims to deliver potent genetic therapies directly to cancer sites, offering a novel and potentially disruptive solution in the fight against cancer.
Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company’s precision genetic medicine platform, which targets both primary and metastatic cancer tumors using engineered viruses. With global cancer diagnoses expected to reach 35 million annually by 2050, Calidi’s approach represents a potential breakthrough in addressing critical unmet needs. The company’s platform aims to deliver potent genetic therapies directly to cancer sites, offering a novel and potentially disruptive solution in the fight against cancer.
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
